important differences in African and Asian individuals for whom the device now automatically adjusts the ESC thresholds for interpretation [15] . This prevents "data from individuals of African descent" from being "falsely reported as abnormal'' as stated by the authors. Therefore, combining subjects with different disorders and different ethnicities is not a scientifically appropriate approach.
Second, Rajan and colleagues mention, "ESC values in individuals with chronic type-1 diabetes mellitus also appear to exceed those of control subjects''. However, according to published data [14] , patients with type-1 diabetes mellitus with peripheral neuropathy had mean ESC of 53.5 ± 25.1 μS while controls and type-1 diabetes mellitus without peripheral neuropathy had mean ESC of 77.1 ± 14.3 μS. In a recently published work [1] , patients with type-1 diabetes mellitus whose peripheral neuropathy status was not reported had mean ESC of 82 ± 8 μS. It is also commonly acknowledged that peripheral neuropathy is different in type-1 diabetes mellitus and type-2 diabetes mellitus.
Third, the statement "The coefficient of variation in subjects with diabetes was 32%" is inaccurate. Published data in patients with diabetes [9] show that the coefficient of variation of glycemia (blood glucose) was 32%, whereas the coefficient of variation of ESC in the soles of the patients was 7%. More importantly, the authors fail to cite a more recent publication specifically analyzing ESC reproducibility [2] . Repeatability and reproducibility were tested in both healthy volunteers and patients with type-2 diabetes mellitus. For ESC in the soles, the mean repeatability standard deviation was 2.1 μS (mean coefficient of variation of 2.8 ± 1.6%) and the mean reproducibility standard deviation was 2.3 μS (mean coefficient of variation of 3.1 ± 1.5%) in healthy volunteers, while in patients type-2 diabetes mellitus, the mean repeatability standard deviation was 4.3 μS (mean coefficient of variation was 6.9 ± 6.3%) and the mean repeatability standard deviation was 4.3 μS (mean coefficient Fourth, the authors also question how, following bariatric surgery, "individuals with type-2 diabetes mellitus can regain nerve fiber function that exceeds that of the control group 24 weeks post-surgery" [4] . This is a misinterpretation of results. The study shows significant sudomotor recovery towards normal values 24 weeks after bariatric surgery in the diabetes mellitus group, but it does not exceed that of the control and pre-diabetes groups (Soles ESC at 24 weeks: diabetes mellitus: 70.1 ± 2.8; pre-diabetes: 71.2 ± 2.3; and non-diabetes: 71.3 ± 2.3. See [4] ). Furthermore, excessive sweating during recovery following sudomotor nerve injury has been previously demonstrated by Gibbons and colleagues [8] . Similarly, Boyd and colleagues demonstrated rapid C-fiber recovery following 18-week treatment with topiramate [3] . While excessive sweating is likely only temporary and needs further investigation, dismissing the results as "biologically implausible" is shortsighted.
Fifth, the authors criticize that that the manufacturer of the ESC device funded many published studies. However, among the 25 "funded" investigators, three received only a loan of the device to test the technology and data are consistent between funded and non-funded researchers. Recent publications and presentations on the diagnosis and followup of hereditary transthyretin (TTR) amyloidosis polyneuropathy emphasize the sensitivity, reproducibility, and thus clinical utility of ESC for the detection of small fiber neuropathy in this disorder [6, 10] . Impeto Medical did not fund this research.
Sixth, Chizmazdhev and colleagues [7] showed that the only way chloride ions can be extracted through skin at voltages below 10 V is via sweat ducts, providing evidence that ESC is a sweat test. In contrast, the sudomotor mechanism underlying sympathetic skin conductance still remains uncertain. ESC has been correlated with measures of small fiber neuropathy [5, 11, 12] and the results have been consistent throughout different centers and across different countries. Importantly, a systematic review by Novak, also published in this issue of Clinical Autonomic Research, concludes that ESC has clinical utility due to its sensitivity and especially its superior reproducibility compared to other sudomotor tests currently available [12] .
We acknowledge and agree with Rajan and colleagues that additional mechanistic and clinical studies are needed to better understand the in vivo physiology and target of ESC measurements. However, this should not dispel the fact that ESC measurements have promising value in clinical practice. Currently, there is a need for an objective test to evaluate neuropathy that can be extensively applied in a growing, at-risk adult population. ESC quantification is currently the simplest (less than 5 min) and most accessible noninvasive test that is able to do so.
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